Show Me the Data: Immunotherapy Across the Hepatobiliary Cancer Continuum—From Embolization-Eligible HCC to Advanced Biliary Tract Cancers

Overview:

The management of hepatobiliary cancers (HBCs), including hepatocellular carcinoma (HCC) and biliary tract cancers (BTC), is rapidly evolving as immunotherapy-based strategies expand across multiple disease settings. Despite significant advances, clinical challenges remain, including selecting among multiple first-line immunotherapy regimens for advanced HCC, integrating systemic immunotherapy with locoregional approaches such as TACE, and incorporating emerging chemoimmunotherapy and biomarker-driven strategies in BTC.

This hybrid satellite symposium, presented adjunct to the 2026 AASLD The Liver Meeting, will use the interactive Show Me the Data™ format to review emerging clinical evidence through patient cases and clinical decision points. Expert faculty will discuss treatment selection and multidisciplinary strategies across the HCC and BTC treatment continuum.

Learning Objectives:

Upon completion of this activity, participants will be able to:

• Assess the clinical significance of emerging data on immunotherapy-based combination regimens for patients with embolization-eligible and advanced unresectable HCC
• Develop individualized first-line treatment strategies for patients with hepatocellular and biliary tract cancers by applying data from recent Phase 3 trials
• Develop a multidisciplinary framework for incorporating next-generation immunotherapy approaches into the hepatobiliary cancer treatment continuum

Target Audience:

This educational activity is directed toward hepatologists, medical, surgical, and radiation oncologists, as well as advanced practitioners, nurses, pharmacists, and other healthcare providers involved in the management of hepatobiliary cancers.

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Medical Oncologists (ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.